ClinicalTrials.gg
RecruitingNCT07691840CAREGIVERUpdated Nov 17, 2026

Intrathecal Therapy Versus Standard Care for Severe Cancer Pain

An interventional study of Intrathecal Drug Delivery and Comprehensive Medical Management in Intrathecal Drug Delivery, Refractory Cancer Pain and Conventional Medical Management, sponsored by Universitair Ziekenhuis Brussel. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Universitair Ziekenhuis Brussel · Not applicable, Interventional, and Treatment

How we know

Updated Nov 17, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Approximately 66% of patients with advanced cancer experience pain, which is often inadequately controlled and associated with a decline in health-related quality of life (HRQoL). Conventional pharmacologic management, ranging from simple analgesics to strong opioids, is frequently limited by insufficient efficacy and systemic side effects. Intrathecal drug delivery (IDD) offers targeted, continuous medication infusion directly into the intrathecal space, allowing lower systemic doses and potentially reducing side effects while maintaining effective analgesia. The CAREGIVER study is a randomized, controlled trial designed to evaluate whether patients with severe refractory cancer pain receiving IDD experience a difference in HRQoL compared to those receiving conventional medical management (CMM) with oral pain medications.

02

Conditions studied

  • Intrathecal Drug Delivery
  • Refractory Cancer Pain
  • Conventional Medical Management

Browse trials for

Keywords

  • Intrathecal pumps
  • Intrathecal drug delivery
  • Refractory cancer pain
  • Health-related quality of life
  • Neuromodulation
03

In context

Cancer Pain

311 studies on the registry are indexed under Cancer Pain; 74 are open to participants now.

This study's planned enrollment of 72 is above the median of 63 across 236 interventional studies indexed under Cancer Pain.

Browse Cancer Pain studies →

Lead sponsor

Universitair Ziekenhuis Brussel is the lead sponsor of 375 studies on the registry; 107 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (≥18 years) with severe cancer pain (all types of cancer), who have been receiving treatment with oral/systemic opioids for at least 4 weeks, and are expected to remain on opioids for the entire duration of the study. More than one opioid rotation has to be done before defining pain refractoriness.
  • Intrathecal therapy is recommended because of inefficacy or intolerance to strong systemic opioid treatment. Inefficacy is defined as mean daily visual analogue scale (VAS) pain intensity score at rest of ≥ 50 mm. Intolerance is defined as the occurrence of (S)AEs (even with dosage less than 200 mg/day of oral morphine equivalents) which prevents a further increase in the opioid dosage to obtain pain relief.
  • Patients suitable for IDD and with the ability to comply with the medical protocol and visits.
  • Survival prognosis of ≥ 6 months.

Exclusion criteria

Exclusion Criteria:

  • Patients with active, severe infection.
  • Patients with known .
  • Patients with high risk of hemorrhaging.
  • Patients with respiratory depression (for use of morphine).
  • Patients with severe respiratory compromise; baseline oxygen SpO2 \< 90%, chronic CO2 retention.
  • Patients with severe cardiac disease or risk of cardiotoxicity (for use of bupivacaine).
  • Patients with severe liver impairment or liver failure (for use of ropivacaine).
  • Patients with allergies for medication or IDD hardware.
  • Pregnant or lactating women.
  • Women who plan to become pregnant within 1 month after the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Active comparator
    Intrathecal Drug Delivery

    Procedure: Intrathecal Drug Delivery

  • Active comparator
    Comprehensive Medical Management

    Drug: Comprehensive Medical Management

Interventions

  • ProcedureIntrathecal Drug Delivery

    Patients assigned to the IDD-group (intervention group) will undergo implantation of an IDD pump (Synchromed™, Medtronic). The device will be placed subcutaneously in the abdominal region and connected to a catheter delivering pain medication directly into the intrathecal space surrounding the spinal cord. At the time of implantation, the pump will be filled with medication, such as morphine, local anesthetics, or a combination thereof, and an initial daily dose will be selected. In the days following surgery, dose titration will be performed to establish the optimal balance between pain relief and tolerability. Following implantation, the most common postoperative procedure is the drug refill. This involves aseptic access to the pump reservoir, removal of any residual volume, and replenishment with a fresh dose of medication. Refill intervals will depend on the patient's daily dosage, ranging from monthly to once every 2-3 months.

  • DrugComprehensive Medical Management

    Participants randomized to the CMM-group will receive standard care.

06

What researchers measure

Primary outcomes

  1. Health-related quality of life

    Health-related quality of life will be evaluated with the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30).

    Time frame: At baseline and 1, 2, 4, 6, 8, 10, and 12 months post-treatment initiation

Secondary outcomes

  1. Patient comfort

    Patient comfort is evaluated with the General Comfort Questionnaire (GCQ), a self-reported instrument consisting of 48 items that reflect the physical, spiritual, environmental, and social dimension.

    Time frame: At baseline and 1, 2, 4, 6, and 12 months post-treatment initiation

  2. Survival

    The survival rate will be determined by recording the time from treatment initiation until death.

    Time frame: At baseline and 1, 2, 4, 6, and 12 months post-treatment initiation

  3. Pain intensity

    Pain intensity will be measured with the Visual Analogue Scale (ranging from 0 (no pain) to 100 (maximal pain)) in electronic format. Momentary data collection will be used to collect pain intensity scores for VAS (valid and reliable for pain experience), whereby pain intensity is measured for multiple times per day for 1 week to reveal patterns of transient or fluctuating symptoms in the environment and context of the patients' lives, without a recall bias.

    Time frame: At baseline and 1, 2, 4, 6, 8, 10, and 12 months post-treatment initiation

  4. Perceived stress

    Perceived stress will be assessed by using the 10-item Perceived Stress Scale.

    Time frame: At baseline and 1, 2, 4, 6, and 12 months post-treatment initiation

  5. Anxiety

    Patient anxiety will be provided through the State Trait Anxiety Inventory (STAI).

    Time frame: At baseline and 1, 2, 4, 6, and 12 months post-treatment initiation

  6. Perceived Injustice

    Using the Injustice Experience Questionnaire (IEQ), perceived injustice related to current health status will be assessed.

    Time frame: At baseline and 1, 2, 4, 6, and 12 months post-treatment initiation

  7. Self-efficacy

    The General Self-Efficacy (GSE) Scale is a 10-item self-report questionnaire used to assess perceived self-efficacy.

    Time frame: At baseline and 1, 2, 4, 6, and 12 months post-treatment initiation

  8. Caregiver burden

    To evaluate caregiver burden, the Zarit Burden Interview (ZBI) questionnaire will be completed. This 12-item self-report instrument assesses caregiver burden and is a shortened version of the original 22-item Zarit Burden Scale.

    Time frame: At baseline and 1, 2, 4, 6, and 12 months post-treatment initiation

  9. Health expenditure

    Expenditures related to in-hospital care will be extracted from hospital claims data. All other healthcare-related costs will be gathered through telephone interviews with patients, conducted each month after treatment initiation. During these calls, researchers will ask patients whether they have had any medical consultations, hospital admissions, AEs, changes in medication (such as daily morphine, MED, antidepressants,…), or incurred any additional healthcare costs.

    Time frame: monthly after treatment initiation until 12 months

  10. Safety

    Recording of (serious) adverse events.

    Time frame: Throughout the duration of the study, an average of 12 months.

  11. Number of responders

    Responder status will be determined based on pain scores, adverse events, and medication dose changes. Responders are defined as patients achieving a clinically meaningful reduction in pain intensity (≥30% from baseline) without intolerable adverse effects.

    Time frame: at 1, 2, 4, 6, and 12 months post-treatment initiation

07

Study locations

1 of 1 sites recruiting
  • UZ Brussel
    Jette, 1090, Belgium
    Recruiting
    • Maarten Moens, MD PhD MBA · Contactstimulusresearchgroup@gmail.com · +3224775514
    • Ulrike Van Hoey, MSc · Sub investigator
    • Britt Winnepenninckx, MSc · Sub investigator
    • Lisa Goudman, MSc, PhD · Sub investigator
    • Mark De Ridder, MD PhD · Sub investigator
    • Maarten Moens, MD PhD MBA · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Oct 2029, 35 months after the start.

Of 73 non-industry interventional studies with no phase under Cancer Pain, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 35 months is above that.

Counting every sponsor, half of 76 studies reached it within 18 months; a quarter within 10 and three quarters within 40.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Nov 2026, on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2026
First posted
Jul 9, 2026
StartActual
Nov 4, 2026was Jul 2026
Primary completionEst.
Oct 31, 2029
CompletionEst.
Oct 31, 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 1, 2026→Nov 4, 2026 (actual)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Start date Jul 1, 2026→Nov 4, 2026 (now actual)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07691840
Responsible party
Moens Maarten (principal investigator, Universitair Ziekenhuis Brussel) — Principal investigator
First posted
Jul 9, 2026
Start date
Nov 4, 2026
Primary completion
Oct 31, 2029 (estimated)
Completion
Oct 31, 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

Maarten Moens, MD PhD MBA
Contact
stimulusresearchgroup@gmail.com
+3224775514
Lisa Goudman, MSC, PhD
Contact
lisa.goudman@vub.be
+32472412507

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion